How to Control Impurities during API drug manufacturing
Posted: February 19, 2018
Dr. Rajesh Shukla, Vice President Research and Development at PCI Synthesis Talks about Controlling Impurities during API drug manufacturing.
Related posts:
How the U.S. Can Raise the Next Generation of API Manufacturing Talent
Ensuring Industry Compliance in Identifying Genotoxic Impurities in APIs
Seqens CDMO North America Honored for Service Excellence for 6th Straight Year
When it Comes to API Manufacturing, Face Masks and Clean Environments Have Always Been Part of Life
Why API manufacturing projects go over budget?